StreetInsider.com News Articles

Xeris Biopharma presents data on Gvoke, Recorlev at fall meetings

Thu, 15 Oct 2026 08:04:28 -0400

Xeris Biopharma Holdings (Nasdaq: XERS) announced clinical and scientific data presentations from its commercial portfolio and pipeline at three scientific meetings this fall, covering its Gvoke, Recorlev, and investigational XP-8121 programs.

At the Breakthrough T1D Clinical & Research Congress on Oct. 9 in Philadelphia, the company presented real-world data examining the gap between physician awareness of American Diabetes Association guidelines for prescribing ready-to-use glucagon and actual prescribing practices for Gvoke.

At the Annual Cardiometabolic Health Congress on Oct. 15–16 in Boston, a case study was presented showing cortisol normalization following treatment with Recorlev (levoketoconazole) in a patient with uncontrolled Type 2 diabetes

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

Thu, 15 Oct 2026 08:00:00 -0400

Clinical and scientific data presentations in support of Gvoke® (glucagon) injection, Recorlev® (levoketoconazole), and the investigational XP-8121 program underscore Xeris's leadership in endocrinology, including the treatments for Severe Hypoglycemia, Cushing's Syndrome, and Hypothyroidism

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced clinical and scientific data presentations from its commercial portfolio and development pipeline at three scientific meetings this fall: Breakthrough T1D Clinical & Research Congress (CRC), the 21st Annual Cardiometabolic Health Congress

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

Thu, 15 Oct 2026 08:00:00 -0400

Form 8-K Xeris Biopharma Holdings For: Oct 13

Wed, 14 Oct 2026 07:08:00 -0400

si-local-file:///var/storage/secattach/20261014/27183592.html

Xeris Pharmaceuticals (XERS) PT Raised to $14 at Barclays

Tue, 06 Oct 2026 03:26:58 -0400

Barclays analyst Jenna Davidner raised the price target on Xeris Pharmaceuticals (NASDAQ: XERS) to $14.00 (from $12.00) while maintaining a Overweight rating.

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 17:00:00 -0400

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2026, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options and restricted stock units for an aggregate of 352,170 shares of its common stock to 60 new employees under Xeris’ Inducement Equity Plan.

Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 17:00:00 -0400

Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as

Form 4 Xeris Biopharma Holdings For: Oct 01 Filed by: McCulloch Kevin

Fri, 02 Oct 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20261002/27143210.html

Form 4 Xeris Biopharma Holdings For: Oct 01 Filed by: Pieper Steven

Fri, 02 Oct 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20261002/27143217.html

Form 4 Xeris Biopharma Holdings For: Oct 01 Filed by: Hecht Beth

Fri, 02 Oct 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20261002/27143205.html

Form 144 Xeris Biopharma Holdings Filed by: Hecht Beth

Thu, 01 Oct 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20261001/27136375.html

Form 4 Xeris Biopharma Holdings For: Sep 28 Filed by: McCulloch Kevin

Tue, 29 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260929/27123253.html

Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports

Tue, 29 Sep 2026 16:00:40 -0400

Investing.com -- H Lundbeck (LON:0ND5) has expressed interest in a potential takeover of Chicago-based commercial-stage drugmaker Xeris Pharmaceuticals Inc (NASDAQ:XERS), according to people familiar with the matter cited by Bloomberg. The Danish pharmaceutical group has been working with financial advisers to explore an acquisition of the U.S. firm, though discussions remain preliminary and may not result in a formal transaction.

Shares of Xeris have surged almost 20% over the past 12 months, lifting the company’s market valuation to approximately $1.8 billion. By comparison, Lundbeck holds a market capitalization of roughly 43.3 billion Danish kroner ($6.6

Lundbeck approaches Xeris Biopharma over potential takeover, Bloomberg reports

Tue, 29 Sep 2026 16:00:40 -0400

Lundbeck said to explore acquisition of Xeris Biopharma - Bloomberg

Tue, 29 Sep 2026 12:41:16 -0400

(Updated - September 29, 2026 12:41 PM EDT)

H. Lundbeck A/S has expressed interest in acquiring Xeris Biopharma Holdings Inc., a commercial-stage drugmaker, according to people familiar with the matter cited by Bloomberg.

The Danish pharmaceutical company has been working with advisers to explore a potential takeover of Chicago-based Xeris, according to the sources, who requested anonymity due to the confidential nature of the discussions.

Lundbeck said to explore acquisition of Xeris Biopharma - Bloomberg

Tue, 29 Sep 2026 12:41:16 -0400

(Updated - September 29, 2026 12:41 PM EDT)

H. Lundbeck A/S has expressed interest in acquiring Xeris Biopharma Holdings Inc., a commercial-stage drugmaker, according to people familiar with the matter cited by Bloomberg.

Lundbeck said to explore acquisition of Xeris Biopharma - Bloomberg

Tue, 29 Sep 2026 12:41:16 -0400

(Updated - September 29, 2026 12:41 PM EDT)

H. Lundbeck A/S has expressed interest in acquiring Xeris Biopharma Holdings Inc., a commercial-stage drugmaker, according to people familiar with the matter cited by Bloomberg.

Lundbeck said to explore acquisition of Xeris Biopharma - Bloomberg

Tue, 29 Sep 2026 12:41:16 -0400

(Updated - September 29, 2026 12:41 PM EDT)

H. Lundbeck A/S has expressed interest in acquiring Xeris Biopharma Holdings Inc., a commercial-stage drugmaker, according to people familiar with the matter cited by Bloomberg.

Form 144 Xeris Biopharma Holdings Filed by: McCulloch Kevin

Mon, 28 Sep 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260928/27114721.html

Oppenheimer Reiterates Outperform Rating on Xeris Pharmaceuticals (XERS)

Thu, 10 Sep 2026 06:11:50 -0400

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $18.00 price target on Xeris Pharmaceuticals (NASDAQ: XERS).

The analyst commented: "Yesterday's virtual event provided an overview of Xeris Biopharma's clinical, regulatory, and commercial plans for XP-8121, its once-weekly subcutaneous levothyroxine candidate for hypothyroidism. In our view, KOL commentary and the design of the soon-to-begin Phase 3 Cornerstone trial derisk XP-8121's opportunity, aimed at the 3-5M US patients who remain biochemically uncontrolled on oral levothyroxine. The concurrent Touchstone trial will provide additional real-world evidence of unmet need and clinical differentiation from standard of care. We see XP-8121 launching in 2030, and management

Xeris Announces Details for XP-8121 Program Overview Webinar

Wed, 26 Aug 2026 07:30:00 -0400

Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism.

The XP-8121 webinar will take place on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist, alongside members of the Xeris program team.

Xeris Announces Details for XP-8121 Program Overview Webinar

Wed, 26 Aug 2026 07:30:00 -0400

Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism.

The XP-8121 webinar will take place on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist, alongside members of the Xeris program team.

Xeris Announces Details for XP-8121 Program Overview Webinar

Wed, 26 Aug 2026 07:30:00 -0400

Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism.

The XP-8121 webinar will take place on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist, alongside members of the Xeris program team.

Xeris Announces Details for XP-8121 Program Overview Webinar

Wed, 26 Aug 2026 07:30:00 -0400

Webinar to Highlight Unmet Needs in Hypothyroidism, Market Opportunity, and Planned Phase 3 Program for XP-8121

CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism.

The XP-8121 webinar will take place on Wednesday, September 9, 2026, at 10 a.m. ET and will feature a leading endocrinologist, alongside members of the Xeris program team.

Form 4 Xeris Biopharma Holdings For: Aug 01 Filed by: Shannon John Patrick Jr

Fri, 21 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260821/26961696.html